The association between fibrinogen-to-albumin ratio (FAR) and adverse prognosis in patients with acute decompensated heart failure at different glucose metabolic states

Table 3 The HR (95% CI) of MACCEs according to FAR and different glucose metabolism states from the three models

Glucose regulation state	FAR	Events, n (%)	Model 1		Model 2		Model 3
Glucose regulation state	FAR	Events, n (%)	HR (95% CI)	p-Value	HR (95% CI)	p-Value	HR (95% CI)	p-Value
Total	Low	182 (17.7)	Ref.		Ref.		Ref.
Total	High	301 (29.2)	1.32 (1.09–1.59)	0.003	1.29 (1.07–1.55)	0.008	1.29 (1.07–1.56)	0.007
DM	Low	86 (8.3)	Ref.		Ref.		Ref.
DM	High	189 (18.3)	1.52 (1.17–1.96)	0.002	1.46 (1.13–1.89)	0.004	1.48 (1.14–1.92)	0.003
Pre-DM	Low	55 (5.3)	Ref.		Ref.		Ref.
Pre-DM	High	64 (6.2)	1.01 (0.70–1.45)	0.946	0.96 (0.66–1.39)	0.814	0.95 (0.65–1.39)	0.799
NGR	Low	41 (4.0)	Ref.		Ref.		Ref.
NGR	High	48 (4.7)	1.18 (0.77–1.82)	0.432	1.13 (0.71–1.79)	0.591	1.10 (0.69–1.73)	0.693

Model 1: Adjusted for gender, age, BMI, SBP, DBP, and heart rate. Model 2: Adjusted for Model 1 + BNP, creatinine, WBC, sodium, UA, ALT, and LVEF. Model 3: Adjusted for Model 2 + history of hypertension, valvular heart disease, atrial fibrillation, and use of aldosterone antagonist, β-Blockers, ACEI/ARB/ARNI, and SGLT2i
CI Confidence interval; FAR Fibrinogen-to-albumin ratio; HR Hazard ratio

ISSN: 1475-2840